A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer's disease

被引:66
|
作者
He, Qiliang [1 ,2 ]
Colon-Motas, Kay M. [3 ]
Pybus, Alyssa F. [1 ,2 ,4 ,5 ]
Piendel, Lydia [3 ]
Seppa, Jonna K. [3 ]
Walker, Margaret L. [3 ,6 ]
Manzanares, Cecelia M. [3 ,6 ]
Qiu, Deqiang [1 ,2 ,6 ,7 ]
Miocinovic, Svjetlana [1 ,2 ,3 ,6 ]
Wood, Levi B. [1 ,2 ,4 ,5 ]
Levey, Allan I. [3 ,6 ]
Lah, James J. [3 ,6 ]
Singer, Annabelle C. [1 ,2 ]
机构
[1] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr,UAWSuite 3105, Atlanta, GA 30332 USA
[2] Emory Univ, Atlanta, GA 30332 USA
[3] Emory Univ, Emory Brain Hlth Ctr, Dept Neurol, Atlanta, GA USA
[4] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA USA
[5] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA USA
[6] Emory Univ, Goizueta Alzheimer Dis Res Ctr, Atlanta, GA USA
[7] Emory Univ, Dept Radiol & Imaging Sci, Sch Med, Atlanta, GA USA
关键词
amyloid beta; cytokines; default mode network; electrophysiology; feasibility trial; gamma stimulation; neural stimulation; prodromal Alzheimer's disease; sensory stimulation; PHASE-I TRIAL; STEM-CELLS; BRAIN; STIMULATION; MICROGLIA;
D O I
10.1002/trc2.12178
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction We and collaborators discovered that flickering lights and sound at gamma frequency (40 Hz) reduce Alzheimer's disease (AD) pathology and alter immune cells and signaling in mice. To determine the feasibility of this intervention in humans we tested the safety, tolerability, and daily adherence to extended audiovisual gamma flicker stimulation. Methods Ten patients with mild cognitive impairment due to underlying AD received 1-hour daily gamma flicker using audiovisual stimulation for 4 or 8 weeks at home with a delayed start design. Results Gamma flicker was safe, tolerable, and adherable. Participants' neural activity entrained to stimulation. Magnetic resonance imaging and cerebral spinal fluid proteomics show preliminary evidence that prolonged flicker affects neural networks and immune factors in the nervous system. Discussion These findings show that prolonged gamma sensory flicker is safe, tolerable, and feasible with preliminary indications of immune and network effects, supporting further study of gamma stimulation in AD.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Biomarkers and Functional Decline in Prodromal Alzheimer's Disease
    Robb, Catherine
    Udeh-Momoh, Chinedu
    Wagenpfeil, Stefan
    Schoepe, Jakob
    Alexopoulos, Panagiotis
    Perneczky, Robert
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 58 (01) : 69 - 78
  • [32] Exploring Alzheimer's disease subtypes at the prodromal stage
    Kolanko, Magdalena A.
    Malhotra, Paresh A.
    BRAIN, 2018, 141 : 3285 - 3287
  • [33] Brainstem substructures and cognition in prodromal Alzheimer’s disease
    Shubir Dutt
    Yanrong Li
    Mara Mather
    Daniel A. Nation
    Brain Imaging and Behavior, 2021, 15 : 2572 - 2582
  • [34] Neuropsychological assessment in preclinical and prodromal Alzheimer's disease
    Nikolai, Tomas
    INTERNATIONAL JOURNAL OF PSYCHOLOGY, 2024, 59 : 453 - 453
  • [35] A Case of Minimally Progressive Prodromal Alzheimer's Disease
    Rosenbloom, Michael H.
    Barclay, Terry
    JOURNAL OF ALZHEIMERS DISEASE REPORTS, 2023, 7 (01) : 37 - 40
  • [36] Cognitive decline in the prodromal phase of Alzheimer's disease
    Orgogozo, J. -M.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 24 - 24
  • [37] Critical Flicker Fusion Threshold in patients with Alzheimer's disease and vascular dementia
    Curran, S
    Wilson, S
    Musa, S
    Wattis, J
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2004, 19 (06) : 575 - 581
  • [38] Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease
    Cavedo, Enrica
    Grothe, Michel J.
    Colliot, Olivier
    Lista, Simone
    Chupin, Marie
    Dormont, Didier
    Houot, Marion
    Lehericy, Stephane
    Teipel, Stefan
    Dubois, Bruno
    Hampel, Harald
    SCIENTIFIC REPORTS, 2017, 7
  • [39] APECS TRIAL OF THE BACE1 INHIBITOR VERUBECESTAT FOR PRODROMAL ALZHEIMER'S DISEASE.
    不详
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2018, 5 (04): : S1 - S196
  • [40] Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease
    Teipel, Stefan J.
    Cavedo, Enrica
    Grothe, Michel J.
    Lista, Simone
    Galluzzi, Samantha
    Colliot, Olivier
    Chupin, Marie
    Bakardjian, Hovagim
    Dormont, Didier
    Dubois, Bruno
    Hampel, Harald
    NEUROPHARMACOLOGY, 2016, 108 : 128 - 135